Antimalarial dosing regimens and drug resistance

Trends in Parasitology

Volumn 24, Issue 3, 2008, Pages 127-134

  Barnes, Karen I ^a   Watkins, William M ^b   White, Nicholas J ^b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTESUNATE; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; CYCLOGUANIL; DIHYDROARTEMISININ PLUS PIPERAQUINE; FANSIDAR; MEFLOQUINE; PROGUANIL; PROTEINASE INHIBITOR; QUININE; SULFADOXINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; AREA UNDER THE CURVE; CARDIOTOXICITY; CHILDHOOD; COMORBIDITY; DISEASE COURSE; DISEASE TRANSMISSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG METABOLISM; DRUG QUALITY; EPIDEMIC; FETUS DEATH; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; INTERMITTENT PREVENTIVE TREATMENT; LOW BIRTH WEIGHT; MALARIA; MATERNAL MORTALITY; MIXED INFECTION; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PREGNANT WOMAN; PROPHYLAXIS; PUBLIC HEALTH; REVIEW; RISK FACTOR; TREATMENT FAILURE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALARIA; MALE; MIDDLE AGED; PLASMODIUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; RISK FACTORS; TREATMENT FAILURE;

EID: 39749193827     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2007.11.008     Document Type: Review

References (73)

1. White N.J. The assessment of antimalarial drug efficacy. Trends Parasitol. 18 (2002) 458-464
2. Watkins W.M., and Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans. R. Soc. Trop. Med. Hyg. 87 (1993) 75-78
3. Mendez F., et al. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am. J. Epidemiol. 156 (2002) 230-238
4. A-Elbasit I.E., et al. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics. Malar. J. 6 (2007) 108
5. Bousema J.T., et al. Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya. Trop. Med. Int. Health 8 (2003) 427-430
6. Price R.N., et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 347 (1996) 1654-1658
7. Barnes, K.I. et al. Increasing post-treatment gametocytemia: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. J. Inf. Dis. (In press)
8. Pukrittayakamee S., et al. Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 47 (2003) 3458-3463
9. White N.J., et al. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37 (1999) 105-125
10. Barnes K.I., et al. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: paediatric dosing implications. Clin. Pharmacol. Ther. 80 (2006) 582-596
11. Smithuis F., et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367 (2006) 2075-2085
12. Slutsker L.M., et al. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo / in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull. World Health Organ. 68 (1990) 53-59
13. Denis M.B., et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop. Med. Int. Health 11 (2006) 1800-1807
14. Hietala S.F., et al. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J. Pharmacokinet. Pharmacodyn. 34 (2007) 669-686
15. White, N.J. et al. Simplified antimalarial therapeutic monitoring: using the Day 7 drug level? Trends Parasitol. (In press)
16. White N.J. Quinine loading dose in cerebral malaria. Am. J. Trop. Med. Hyg. 32 (1983) 1-5
17. Hien T.T., et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob Agents Chemother. 48 (2004) 4234-4239
18. Migasena S. Transient total blindness from quinine therapy. Ann. Trop. Med. Parasitol. 79 (1985) 109-110
19. Newton P.N., et al. Early treatment failure in severe malaria resulting from abnormally low plasma quinine concentrations. Trans. R. Soc. Trop. Med. Hyg. 100 (2006) 184-186
20. Pukrittayakamee S., et al. Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 47 (2003) 1509-1513
21. Looareesuwan S., et al. Monotherapy with sodium artesunate for uncomplicated falciparum malaria in Thailand: a comparison of 5- and 7-day regimens. Acta Trop. 67 (1997) 197-205
22. White N.J. Antimalarial drug resistance. J. Clin. Invest. 113 (2004) 1084-1092
23. Anderson T.J., and Roper C. The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop. 94 (2005) 269-280
24. Hastings I.M., and Watkins W.M. Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol. 22 (2006) 71-77
25. Simpson J.A., et al. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother. 44 (2000) 3414-3424
26. Ringwald P., et al. Chemoresistance of P. falciparum in urban areas of Yaounde, Cameroon. Part 1: surveillance of in vitro and in vivo resistance of Plasmodium falciparum to chloroquine from 1994 to 1999 in Yaounde, Cameroon. Trop. Med. Int. Health 5 (2000) 612-619
27. Checchi F., et al. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar. J. 5 (2006) 59
28. Simpson J.A., et al. Population pharmacokinetic and pharmacodynamic modeling of the antimalarial chemotherapy chlorproguanil/dapsone. Br. J. Clin. Pharmacol. 61 (2006) 289-300
29. Alloueche A., et al. Comparison of chorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet 363 (2004) 1843-1848
30. Hung T.Y., et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57 (2004) 253-262
31. Price R.N., et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug resistant malaria. Antimicrob. Agents Chemother. 51 (2007) 4090-4097
32. van Hensbroek M.B., et al. Quinine pharmacokinetics in young children with severe malaria. Am. J. Trop. Med. Hyg. 54 (1996) 237-242
33. Simpson J.A., et al. Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med. 3 (2006) e444
34. Hombhanje F.W., et al. The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br. J. Clin. Pharmacol. 59 (2005) 298-301
35. Ringwald P., et al. Chemoresistance of P. falciparum in urban areas of Yaounde, Cameroon. Part 2: surveillance of efficacy of amodiaquine and sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Cameroon. Trop. Med. Int. Health 5 (2000) 620-627
36. Nosten F., et al. Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria. Br. J. Clin. Pharmacol. 31 (1991) 556-559
37. Desai M., et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect. Dis. 7 (2007) 93-104
38. Fakeye T.O., et al. Therapeutic monitoring of chloroquine in pregnant women with malaria. West Afr. J. Med. 21 (2002) 286-287
39. McGready R., et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur. J. Clin. Pharmacol. 59 (2003) 545-552
40. McGready R., et al. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62 (2006) 367-371
41. McGready R., et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62 (2006) 1021-1031
42. Na Bangchang K., et al. Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 88 (1994) 321-323
43. Green M.D., et al. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J. Infect. Dis. 196 (2007) 1403-1408
44. Abdelrahim I.I., et al. Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria. J. Clin. Pharm. Ther. 32 (2007) 15-19
45. Ward S.A., et al. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect. Dis. 7 (2007) 136-144
46. World Health Organization (2004) A strategic framework for malaria prevention and control during pregnancy in the African region. Brazaville: WHO Regional Office for Africa, 2004: AFR/MAL/04/01
47. White N.J. Intermittent presumptive treatment for malaria. PLoS Med. 2 (2005) e3
48. O'Meara W.P., et al. Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. PLoS Med. 3 (2006) e141
49. Alexander N., et al. Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malar. J. 6 (2007) 9
50. van Eijk A.M., et al. Pregnancy interval and delivery outcome among HIV-seropositive and HIV-seronegative women in Kisumu, Kenya. Trop. Med. Int. Health 9 (2004) 15-24
51. Wolfe E.B., et al. Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight. Am. J. Trop. Med. Hyg. 64 (2001) 178-186
52. Grimwade K., et al. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 18 (2004) 547-554
53. Cohen C., et al. Increased prevalence of severe malaria in HIV-infected adults in South Africa. Clin. Infect. Dis. 41 (2005) 1631-1637
54. Chirenda J., et al. Association of HIV infection with the development of severe and complicated malaria cases at a rural hospital in Zimbabwe. Cent. Afr. J. Med. 46 (2000) 5-9
55. Shah S.N., et al. HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. J. Infect. Dis. 194 (2006) 1519-1528
56. Kamya M.R., et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J. Infect. Dis. 193 (2006) 9-15
57. Van Geertruyden J.P., et al. HIV 1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J. Infect. Dis. 194 (2006) 917-925
58. Khoo S., et al. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 19 (2005) 995-1005
59. German P., et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin. Infect. Dis. 44 (2007) 889-891
60. Simpson J.A., et al. How can we do pharmacokinetic studies in the tropics?. Trans. R. Soc. Trop. Med. Hyg. 95 (2001) 347-351
61. Sibley C.H., et al. A network to monitor antimalarial drug resistance: a plan for moving forward. Trends Parasitol. 24 (2008) 43-48
62. Barnes K.I., et al. World Antimalarial Resistance Network (WARN) IV: clinical pharmacology. Malar. J. 6 (2007) 122
63. Ashley E.A., et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin. Infect. Dis. 41 (2005) 425-432
64. Taylor W.R., et al. Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull. World Health Organ. 84 (2006) 956-964
65. Molyneux E., et al. Children's weights: guess or measure by tape?. Lancet 354 (1999) 1616
66. Terlouw D.J., et al. Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya. J. Infect. Dis. 187 (2003) 467-476
67. Fungladda W., et al. Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull. World Health Organ. 76 (1998) 59-66
68. Ashley E.A., et al. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop. Med. Int. Health 12 (2007) 201-208
69. Ashley E.A., et al. How much fat is necessary to optimize lumefantrine oral bioavailability?. Trop. Med. Int. Health 12 (2007) 195-200
70. Smithuis F., et al. Optimising operational use of artesunate-mefloquine: a randomised comparison of four treatment regimens. Trans. R. Soc. Trop. Med. Hyg. 98 (2004) 182-192
71. Price R.N., et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multi-drug resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 42 (2006) 1570-1577
72. Angus B.J., et al. Oral artesunate dose response relationship in acute falciparum malaria. Antimicrob. Agents Chemother. 46 (2002) 778-782
73. Yeung S., and White N.J. How do patients use malaria drugs? A review of the evidence. Trop. Med. Int. Health 10 (2005) 121-138